EP1461427A4 - Methods for targeted expression of therapeutic nucleic acid - Google Patents

Methods for targeted expression of therapeutic nucleic acid

Info

Publication number
EP1461427A4
EP1461427A4 EP02744307A EP02744307A EP1461427A4 EP 1461427 A4 EP1461427 A4 EP 1461427A4 EP 02744307 A EP02744307 A EP 02744307A EP 02744307 A EP02744307 A EP 02744307A EP 1461427 A4 EP1461427 A4 EP 1461427A4
Authority
EP
European Patent Office
Prior art keywords
methods
nucleic acid
therapeutic nucleic
targeted expression
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02744307A
Other languages
German (de)
French (fr)
Other versions
EP1461427A2 (en
Inventor
Richard R Drake
Saurabh Gupta
Kelly E Mercer
Robyn Mcmasters
Mary Pat Moyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
INCELL Corp LLC
Original Assignee
Eastern Virginia Medical School
INCELL Corp LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Medical School, INCELL Corp LLC filed Critical Eastern Virginia Medical School
Publication of EP1461427A2 publication Critical patent/EP1461427A2/en
Publication of EP1461427A4 publication Critical patent/EP1461427A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
EP02744307A 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid Withdrawn EP1461427A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29783101P 2001-06-13 2001-06-13
US297831P 2001-06-13
US36113702P 2002-03-01 2002-03-01
US361137P 2002-03-01
PCT/US2002/018650 WO2002101076A2 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Publications (2)

Publication Number Publication Date
EP1461427A2 EP1461427A2 (en) 2004-09-29
EP1461427A4 true EP1461427A4 (en) 2006-02-15

Family

ID=26970335

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02744307A Withdrawn EP1461427A4 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Country Status (5)

Country Link
EP (1) EP1461427A4 (en)
JP (1) JP2005504520A (en)
AU (1) AU2002345658A1 (en)
CA (1) CA2460095A1 (en)
WO (1) WO2002101076A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006297112B2 (en) * 2005-10-01 2013-04-18 Charles Stout Regulatable fusion promoters
EP2978854A4 (en) * 2013-03-24 2017-01-11 Oisin Biotechnologies Systems and methods for the targeted production of a therapeutic protein within a target cell
AU2017272104A1 (en) * 2016-05-25 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Activity-dependent expression constructs and methods of using the same
CN110678208B (en) 2017-01-09 2024-04-05 奥依信生物技术公司 Membrane fusion lipid nanoparticles and methods of manufacture and use for producing therapeutic proteins and for therapy
US11603543B2 (en) 2018-04-18 2023-03-14 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein
CN110964747A (en) * 2019-11-26 2020-04-07 深圳市人民医院 Suicide gene adenovirus with high-efficiency specific expression in glioma cell and construction method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
WO2001064739A1 (en) * 2000-03-02 2001-09-07 Ml Laboratories Plc Tcf responsive element

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US6140052A (en) * 1997-03-20 2000-10-31 The Johns Hopkins University cMYC is regulated by Tcf-4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
WO2001064739A1 (en) * 2000-03-02 2001-09-07 Ml Laboratories Plc Tcf responsive element

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORDONARO M ET AL: "Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the beta-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin.", CELL GROWTH & DIFFERENTIATION : THE MOLECULAR BIOLOGY JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. OCT 1999, vol. 10, no. 10, October 1999 (1999-10-01), pages 713 - 720, XP002355545, ISSN: 1044-9523 *
CHEN R-H ET AL: "Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 11, 1 June 2001 (2001-06-01), pages 4445 - 4449, XP002265164, ISSN: 0008-5472 *
EASWARAN V ET AL: "Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 9, no. 23, 2 December 1999 (1999-12-02), pages 1415 - 1418, XP002206444, ISSN: 0960-9822 *
KORINEK V ET AL: "CONSTITUTIVE TRANSCRIPTIONAL ACTIVATION BY A BETA-CATENIN-TCF COMPLEX IN APC-/- COLON CARCINOMA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 275, 21 March 1997 (1997-03-21), pages 1784 - 1787, XP002070159, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
WO2002101076A3 (en) 2004-07-22
AU2002345658A1 (en) 2002-12-23
JP2005504520A (en) 2005-02-17
CA2460095A1 (en) 2003-12-19
WO2002101076A2 (en) 2002-12-19
EP1461427A2 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
HK1062836A1 (en) Nucleic acid vaccines for prevention of flavivirusinfection
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
EP1448586A4 (en) Therapeutic methods for nucleic acid delivery vehicles
GB2393202B (en) Methods of well treatment
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2003286535A8 (en) Methods of manipulating nucleic acids
EP1514106A4 (en) Targeted therapeutic proteins
EP1551292A4 (en) Method for convection enhanced delivery of therapeutic agents
GB0118373D0 (en) Novel therapeutic method
AU2003280603A8 (en) Method of amplifying nucleic acid
AU2003293099A8 (en) Treatment of dna damage related disorders
AU2003260945A8 (en) Methods of use for thermostable rna ligases
IL162511A (en) Method for determining the biological activity of defibrotide
GB0123401D0 (en) Methods of inducing gene expression
EP1461427A4 (en) Methods for targeted expression of therapeutic nucleic acid
GB0124124D0 (en) Methods of treatment
GB0210741D0 (en) Methods of therapy
EP1637597A4 (en) Method of nucleic acid infusion
HUP0402298A3 (en) Use of desoxypeganine for treating clinical depression
GB0218215D0 (en) Amplification of nucleic acids
AU2003256280A1 (en) Methods of delivering gene therapy agents
AU2003272498A8 (en) Fragmentation of dna
EP1435389A4 (en) Method of evaluating efficacy of nucleic acid therapy
GB2384308B (en) Methods of nucleic acid amplification
AU2003293581A8 (en) Method of identifying therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060102

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060330